Analysis of the levonorgestrel-releasing intrauterine system in women with endometriosis

Journal of International Medical Research

Volumn 41, Issue 3, 2013, Pages 548-558

  Lan, Shen ^a   Ling, Liu ^a   Jianhong, Zhao ^a   Xijing, Jiang ^a   Lihui, Wang ^a  

^a Red Cross Hospital of Hangzhou   (China)

Author keywords

Endometriosis; gonadotropin releasing hormone analogue; levonorgestrel releasing intrauterine system; meta analysis

Indexed keywords

CA 125 ANTIGEN; GONADORELIN DERIVATIVE; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL PAIN; AMENORRHEA; ARTICLE; BLEEDING DISORDER; CA 125 ANTIGEN BLOOD LEVEL; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG USE; ENDOMETRIOSIS; FEMALE; GENERAL WELLBEING; HUMAN; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; MAJOR CLINICAL STUDY; META ANALYSIS; OVARY CYST; PAIN; PAIN ASSESSMENT; PREMENOPAUSE; PROTEIN BLOOD LEVEL; PSYCHOLOGICAL WELL BEING; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYSTEMATIC REVIEW; UTERUS SURGERY; VASOMOTOR DISORDER; VISUAL ANALOG SCALE; WELLBEING;

ENDOMETRIOSIS; GONADOTROPIN-RELEASING HORMONE ANALOGUE; LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM; META-ANALYSIS;

CA-125 ANTIGEN; CHOLESTEROL, LDL; CONTRACEPTIVE AGENTS, FEMALE; DATABASES, BIBLIOGRAPHIC; ENDOMETRIOSIS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MEMBRANE PROTEINS; PAIN MEASUREMENT; PREMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84887389147     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513479865     Document Type: Article

References (44)

1. Winkel CA.Evaluation and management of women with endometriosis.Obstet Gynecol. 2003;102:397-408.
2. Henderson AF,Studd JWWModern approaches to endometriosis. Thomas ERock J, ed. Dordrecht, The Netherlands: Kulwer Academic Publishers; 1991:275-290.
3. Lockhat FB,Emembolu JO,Konje JC.The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease.Hum Reprod. 2004;19:179-184.
4. Prentice A, Deary AJ, Goldbeck-Wood S,et al.Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2000; CD000346.
5. Huirne JA,Lambalk CB.Gonadotropin-releasing-hormone-receptor antagonists.Lancet. 2001;358:1793-1803.
6. Vercellini P,Somigliana E,Viganò P,et al.Endometriosis: current and future medical therapies.Best Pract Res Clin Obstet Gynaecol. 2008;22:275-306.
7. d'Arcangues C.WHO statement on hormonal contraception and bone health.Contraception. 2006;73:443-444.
8. Batzer FR.GnRH analogs: options for endometriosis-associated pain treatment.J Minim Invasive Gynecol. 2006;13:539-545.
9. Luukkainen T,Lähteenmäki P,Toivonen J.Levonorgestrel-releasing intrauterine device.Ann Med. 1990;22:85-90.
10. Maruo T,Laoag-Fernandez JB,Pakarinen P,et al.Use of the levonorgestrel intrauterine system on proliferation and apoptosis in the endometrium.Hum Reprod. 2001;16:2103-2108.
11. Vercellini P,Viganò P,Somigliana E.The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis.Curr Opin Obstet Gynecol. 2005;17:359-365.
12. Jensen JT.Contraceptive and therapeutic effects of the levonorgestrel intrauterine system: an overview.Obstet Gynecol Surv. 2005;60:604-612.
13. Lethaby AE, Cooke I and Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005; CD002126.
14. Whiting P,Rutjes A,Reitsma J,et al.The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews.BMC Med Res Methodol. 2003;3:25-25.
15. Lethaby A, Farquhar C and Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; CD000249.
16. Petta CA,Ferriani RA,Abrao MS,et al.Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis.Hum Reprod. 2005;20:1993-1998.
17. Gomes MK,Ferriani RA,Rosa e Silva JC,et al.The levonorgestrel-releasing intrauterine system and endometriosis staging.Fertil Steril. 2007;87:1231-1234.
18. Ferreira RA,Vieira CS,Rosa e Silva JC,et al.Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue.Contraception. 2010;81:117-122.
19. de Sá Rosa e Silva AC,Rosa e Silva JC,Nogueira AA,et al.The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis.Fertil Steril. 2006;86:742-744.
20. Bayoglu Tekin Y,Dilbaz B,Altinbas SK,et al.Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue.Fertil Steril. 2011;95:492-496.
21. Vercellini P,Crosignani PG,Abbiati A,et al.The effect of surgery for symptomatic endometriosis: the other side of the story.Hum Reprod Update. 2009;15:177-188.
22. Hurskainen R,Teperi J,Rissanen P,et al.Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up.JAMA. 2004;291:1456-1463.
23. Guidice LC.Endometriosis.N Engl J Med. 2010;362:2389-2398.
24. Mishell DR.Non-contraceptive health benefits of oral steroidal contraceptives.Am J Obstet Gynecol. 1982;142:809-816.
25. Sivin I,Stern J,Coutinho E,et al.Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag IUDS.Contraception. 1991;44:473-480.
26. Sivin I,Stern J.Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR).Fertil Steril. 1994;61:70-77.
27. Soysal S,Soysal ME.The effi{ligature}cacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial.Gynecol Obstet Invest. 2005;59:29-35.
28. Grigorieva V,Chen-Mok M,Tarasova M,et al.Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas.Fertil Steril. 2003;79:1194-1198.
29. Schroder AK,Diedrich K,Ludwig M.Medical management of endometriosis: a systematic review.IDrugs. 2004;7:451-463.
30. Nilsson CG,Luukkainen T,Arko H.Endometrial morphology of women using a d-norgestrel-releasing intrauterine device.Fertil Steril. 1978;29:397-401.
31. Hurskainen R,Salmi A,Paavonen J,et al.Expression of sex steroid receptors and Ki-67 in the endometria of menorrhagic women: effects of intrauterine levonorgestrel.Mol Hum Reprod. 2000;6:1013-1018.
32. Viganò P,Somigliana E,Vercellini P.Levonorgestrel-releasing intrauterine system for the treatment of endometriosis: biological and clinical evidence.Womens Health (Lond Engl). 2007;3:207-214.
33. Lockhat FB,Emembolu JE,Konje JC.Serum and peritoneal fl{ligature}uid levels of levonorgestrel in women with endometriosis who were treated with an intra-uterine contraceptive device containing levonorgestrel.Fertil Steril. 2005;83:398-404.
34. Gomes MK,Rosa e Silva JC,Garcia SB,et al.Effects of the levonorgestrel-releasing intrauterine system on cell proliferation, Fas expression and steroid receptors in endometriosis lesions and normal endometrium.Hum Reprod. 2009;24:2736-2745.
35. Toki T,Kubota J,Lu X,et al.Immunohistochemical analysis of CA125, CA19-9, and Ki-67 in stage III or IV endometriosis: positive correlation between serum CA125 level and endometriotic epithelial cell proliferation.Acta Obstet Gynecol Scand. 2000;79:771-776.
36. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997; 67: 817-821.
37. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).JAMA. 2001;285:2486-2497.
38. Nilsson CG,Allonen H,Diaz J,et al.Two years' experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device: a randomized comparative performance study.Fertil Steril. 1983;39:187-192.
39. Bragheto AM,Caserta N,Bahamondes L,et al.Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging.Contraception. 2007;76:195-199.
40. Cho S,Nam A,Kim H,et al.Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis.Am J Obstet Gynecol. 2008;198:373.e1-7.
41. Haimovich S,Checa MA,Mancebo G,et al.Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device.Menopause. 2008;15:1002-1004.
42. Beatty MN,Blumenthal PD.The levonorgestrel-releasing intrauterine system: safety, efficacy, and patient acceptability.Ther Clin Risk Manag. 2009;5:561-574.
43. Sheng J,Zhang WY,Zhang JP,et al.The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis.Contraception. 2009;79:189-193.
44. Vercellini P,Frontino G,De Giorgi O,et al.Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study.Fertil Steril. 2003;80:305-309.